Clinical Trial Update: A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics [Phase 1]

View source ↗

Summary

A completed Phase 1 study evaluating the effects of RO5545965 in participants with negative symptoms of schizophrenia treated with antipsychotics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• RO5545965 (RO5545965)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED